PENG block with phenol provides better pain relieve and mobility, and therefore quality of life, compared to current pain relieve strategies in patients with a hipfracture who are not eligible for surgery
ID
Source
Brief title
Condition
- Bone and joint therapeutic procedures
Health condition
Hip fractures
Research involving
Sponsors and support
Intervention
- Other intervention
Pericapsular Nerve Group Block with Phenol
Outcome measures
Primary outcome
Quality of life
Secondary outcome
- Mobility (direct, after 1 and 4 weeks and 3 months - Mortality (30 days, in hospital, 1 year) - NRS before and directly after, after 1 and 4 weeks or PACSLAC-D before vs directly after, after 1 and 4 weeks - opioid consumption - treatment satisfaction of patient (or proxy) and caregivers (1-10) - quality of dying (QODD) - time to death (in days to months) - Complications
Background summary
In the Netherlands, it is estimated that annually 17.500 patients are admitted to the hospital with a hip fracture. 3% of this population is not eligble for surgery. Pain treatment is often insufficient and with significant side-effects in this frail population. The PENG block with administration of phenol might be a better and longer lasting alternative, thereby improving mobility and nursing care with less complications.
Study objective
PENG block with phenol provides better pain relieve and mobility, and therefore quality of life, compared to current pain relieve strategies in patients with a hipfracture who are not eligible for surgery
Study design
At ward admittance, after intervention, after 1 and 4 weeks, after 3 months
Intervention
Neurolytic (modified) PEricapsular Nerve Group block / hip denervation with ultrasound guidance
Age
Inclusion criteria
- Clinical patients not eligible for surgery conform standard shared decision - Caput-, collum- and pertrochanteric fractures - Informed consent of patient or by proxy
Exclusion criteria
- Subtrochanter and more distal femur fractures - acetabelum fracture - periprostethic fractures - No informed consent
Design
Recruitment
IPD sharing statement
p/a Radboudumc, huispost 628,
Postbus 9101
6500 HB Nijmegen
024 361 3154
commissiemensgebondenonderzoek@radboudumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL9487 |